LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor approved for the treatment of psoriasis (PsO). This report series is based on primary research data collected at one month, six months, and one year post-commercial availability of Cosentyx. Along with awareness and sources of familiarity, the reports assess U.S. dermatologists’ trial, adoption, and use of Cosentyx, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Novartis’s promotional efforts, and benchmarking against other previously launched immune agents.

Questions Answered:  

  • Novartis launched Cosentyx in the United States for moderate to severe PsO in March 2015. What is dermatologists’ level of awareness and familiarity with Cosentyx over the course of the year?
  • Cosentyx entered a busy PsO therapy market containing five branded biological/novel small-molecule oral options, as well as an active pipeline. What are the perceived clinical advantages and disadvantages of Cosentyx compared with other marketed agents used to treat PsO? How are the trial and adoption of Cosentyx tracking compared with other product launches in the PsO market?
  • Cosentyx’s U.S. label recommends it for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, with the potential of use prior to the established PsO-treating biologics. Where do dermatologists expect Cosentyx to fit in the PsO treatment algorithm? What are the current prescribing trends among biologics/novel orals, and how do dermatologists anticipate they will change?
  • Novartis’s Cosentyx is the first IL-17-inhibiting psoriasis treatment to enter the market. What promotional messages and activities is Novartis using to support the Cosentyx launch?


Markets covered: United States.

Primary research: 77 dermatologists surveyed per report wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Psoriasis.

Table of contents

  • Psoriasis - Emerging Therapies - Cosentyx Launch Tracking Wave 2 (US)
    • Key Findings
      • Awareness and Perceptions of Cosentyx
      • Cosentyx Trial and Use
      • Competitive Landscape and Cosentyx’s Promotion
    • Benchmarking Cosentyx Launch Success vs. Analogue Immune Agents
      • Prescriber and Nonprescriber Profiles
        • Cosentyx: Differences Between Prescriber and Nonprescriber Profiles
      • Cosentyx Awareness and Perceptions
        • Unaided and Aided Awareness of Cosentyx
          • Awareness of Cosentyx
          • Familiarity with Cosentyx
          • Cosentyx Attributes of Which Dermatologists Were Not Aware
        • Familiarity with Cosentyx
          • Unaided Awareness of Drugs Currently Available for PsO
          • Unaided Awareness of Drugs Currently Available for PsO
        • Sources of Familiarity with Cosentyx
          • Physician Opinion
        • Initial Reaction to and Interest in Cosentyx
          • Cosentyx Product Profile
          • Initial Reaction to Cosentyx After Viewing Product Profile
          • Physician Interest in Learning More About Cosentyx
          • Initial Reaction to Cosentyx Based on the Following Attributes
        • Impressions of Cosentyx
          • Physician-Rated Uniqueness of Cosentyx Compared with Other Available PsO Agents
          • Physician Opinion
          • Physician Opinion
          • Physician-Rated Risk-Benefit Ratio of Cosentyx
        • Prescriber and Nonprescriber Profiles
          • Cosentyx: Differences Between Prescriber and Nonprescriber Profiles
      • Cosentyx Trial and Use
        • Willingness to Prescribe Cosentyx
          • Physician Willingness to Prescribe Cosentyx
          • Physician-Rated Willingness to Prescribe Cosentyx
        • Number of Patients Currently Receiving Cosentyx
          • Mean Cosentyx Patients and Anticipated New Patient Starts Within the Next Month
          • Use of Cosentyx by Disease Severity
          • Origination of Patients Treated with Cosentyx
        • Anticipated Cosentyx Use
          • Physician Opinion
          • Physician Opinion
          • Candidates for Cosentyx by PsO Disease Severity
          • Candidates for Cosentyx by PsO Disease Severity
          • Candidates for Cosentyx by Treatment History
          • Cosentyx Line of Therapy
          • Cosentyx Line of Therapy If Price Were Not an Issue
          • Physician Opinion
        • Cosentyx Performance on Key Attributes
          • Cosentyx Attribute Ratings Based on Expectations – Wave 2
          • Physician Opinion : Why high satisfaction (8-10)? (n = 19)
          • Physician-Rated Satisfaction with Cosentyx
      • Effectiveness of Face-to-Face Detailing for Cosentyx
        • Cosentyx Sales Representative Frequency and Reach
          • Frequency of Dermatologist Contact with Cosentyx Representative
          • Dermatologists’ Receipt of Patient Education Materials/Samples
          • Dermatologists’ Use of Received Samples with PsO patients
        • Satisfaction with Cosentyx Sales Representative
          • Cosentyx Sales Representative Performance…In Their Own Words
          • Cosentyx Sales Representative Performance
          • Cosentyx Sales Representative Performance
        • Cosentyx Message Recall
          • Physician Opinion
          • Physician Opinion: Suggested Patient Types for Cosentyx
          • Dermatologists Provided Suggestions on Patient Types for Cosentyx
      • Methodology
        • Significance Testing in This Study
        • Significance Testing in This Study
      • Appendix
        • Primary Market Research
          • Years in Practice
          • Regional Distribution of Dermatologists
          • Practice Type
          • Practice Location
          • Mean Number of PsO Patients
        • Additional Information
          • Psoriasis Background: Definition and Types of Psoriasis
          • Psoriasis Background: Prevalence, Characteristics, and Treatment
          • Psoriasis Background: Biologics/Small Molecules Approved for Psoriasis
          • Psoriasis Market News
          • Study Objectives
          • Preferred Biologics or Novel Oral Agents for Each Line
          • Patient Disease Severity
          • Prescription Drug Treatment by PsO Disease Severity
          • Opinions and Advice on Cosentyx for the Treatment of PsO
          • Mean Number of Cosentyx Patient Inquiries per Physician
          • Result of Specific Patient Requests for Cosentyx
          • Physician-Rated Managed Care Approval Process for Cosentyx
          • Dermatologists’ Awareness of Products in Development for PsO
          • Dosage Administration to Patients Who Are/Were Receiving Cosentyx
          • Advice for Novartis…In Their Own Words
          • Defining Psoriasis Severity…In Their Own Words
          • Physician Opinion
          • Physicians Enrolling Patients into Cosentyx’s QuickStart Program
          • Requirement for Managed Care Approval of Cosentyx Prescriptions
          • Products Currently in Clinical Trials for PsO Treatment
          • PsO Treatment Algorithm…In Their Own Words
          • Brand Share of Biologics or Novel Oral Agents Used in PsO
          • Cosentyx Dosing…In Their Own Words
          • Cosentyx Managed Care Approval Process…In Their Own Words
          • Dermatologists’ Familiarity with Products in Development
          • Experience with Cosentyx’s QuickStart Program
          • Physician Opinion
          • Cosentyx Patient Support…In Their Own Words
          • Physician Opinion
          • Patient Response to Biologics or Otezla
          • PsO Products in Development…In Their Own Words
          • Percentage of Patients Starting on Each Biologic/Otezla in the Past Year Who Received It as a First-Line Systemic Therapy
          • Phototherapy Treatment by PsO Disease Severity
          • Physician Opinion
          • Percentage of Patients Who Discontinue on Treatment of Each Biologic/Otezla
          • Physician Opinion
          • Biologics/Novel Oral Agents Discussed by Representatives
          • Efficacy Attributes’ Importance When Choosing a Biologic Agent
          • Safety/Tolerability Attributes’ Importance When Choosing a Biologic
          • Pharmacology Attributes’ Importance When Choosing a Biologic
          • Importance of Patient Benefit-Related Attributes When Choosing a Biologic
          • Importance of Physician Benefit-Related Attributes When Choosing a Biologic
          • Statement Agreement
          • Statement Agreement

    Author(s): Hailing Yang, PhD

    Hailing Yang, Ph.D., is an analyst on the Immune and Inflammatory research team at Decision Resources Group, focusing primarily on psoriasis and psoriatic arthritis. In this role, he conducts primary research via interviews/surveys with medical experts and write market analysis deliverables designed for key decision-makers within the biopharmaceutical industry.

    Prior to joining DRG, Dr. Yang worked at Selecta Biosciences and Bioss USA Antibodies as a consultant. He studied brain cancer and received a Ph.D. from Tufts University, where he held an executive role for Tufts New England Case Competition. Dr. Yang earned a B.S. from Wuhan University in China.

    Related Reports

    Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

    The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

    View Details

    Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

    Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

    View Details

    Psoriasis | Disease Landscape and Forecast | G7 | 2020

    The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

    View Details

    Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

    Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

    View Details